DGDebra J. Gilbert

Debra J. Gilbert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Debra J. Gilbert has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Nancy A. Jenkins

    Mammalian Genetics Laboratory, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, MD 21702, USA

    3 shared publications
  • Neal G. Copeland

    Mammalian Genetics Laboratory, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, MD 21702, USA

    3 shared publications
  • Chan-Young Ock

    14Department of Hematology & Oncology, Seoul National University Hospital, Seoul, Korea

    1 shared publication
  • Claudia Palena

    13Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

    1 shared publication
  • Dandan Li

    Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland

    1 shared publication
  • Duncan Ian Jodrell

    Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK

    1 shared publication

Latest Publications

  • Open Access

    T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer

    by Dandan Li, Nicholas Schaub, Theresa M. Guerin, Tashinga E. Bapiro, Frances M. Richards, Vicky Chen, Keyur Talsania, Parimal Kumar, Debra J. Gilbert, Jerome J. Schlomer, et al.

    The desmoplastic stroma of pancreatic cancers forms a physical barrier that impedes intratumoral drug delivery. Attempts to modulate the desmoplastic stroma to increase delivery of administered chemotherapy have not shown positive clinical results thus far, and preclinical reports in which chemotherapeutic drugs were coadministered with antistromal therapies did not universally demonstrate increased genotoxicity despite increased intratumoral drug levels. In this study, we tested whether TGFβ antagonism can break the stromal barrier, enhance perfusion and tumoral drug delivery, and interrogated cellular and molecular mechanisms by which the tumor prevents synergism with coadministered gemcitabine. TGFβ inhibition in genetically engineered murine models (GEMM) of pancreas cancer enhanced tumoral perfusion and increased intratumoral gemcitabine levels. However, tumors rapidly adapted to TGFβ-dependent stromal modulation, and intratumoral perfusion returned to pre-treatment levels upon extended TGFβ inhibition. Perfusion was governed by the phenotypic identity and distribution of cancer-associated fibroblasts (CAF) with the myelofibroblastic phenotype (myCAFs), and myCAFs which harbored unique genomic signatures rapidly escaped the restricting effects of TGFβ inhibition. Despite the reformation of the stromal barrier and reversal of initially increased intratumoral exposure levels, TGFβ inhibition in cooperation with gemcitabine effectively suppressed tumor growth via cooperative reprogramming of T regulatory cells and stimulation of CD8 T cell–mediated antitumor activity. The antitumor activity was further improved by the addition of anti–PD-L1 immune checkpoint blockade to offset adaptive PD-L1 upregulation induced by TGFβ inhibition. These findings support the development of combined antistroma anticancer therapies capable of impacting the tumor beyond the disruption of the desmoplastic stroma as a physical barrier to improve drug delivery.


  • The genes encoding E-selectin ( SELE ) and lymphotactin ( SCYC1 ) lie on separate chicken chromosomes although they are closely linked in human and mouse

    by Shaun Morroll, Marianne Goodchild, Nigel Salmon, Neal G. Copeland, Debra J. Gilbert, Nancy A. Jenkins, Nat Bumstead, Yvonne Boyd

    Three differentially expressed selectin genes (SELE, SELP, and SELL), important in the initial stages of leukocyte extravasation, have been reported in mammals. All three genes map close to the chemokine SCYC1 (small inducible cytokine subfamily C, member 1) in a large conserved chromosomal segment that extends from RXRG (retinoic acid receptor, gamma) to TNNT2 (troponin T2) on Chromosome (Chr) 1 in both human and mouse. In the mouse, we demonstrate that Sele is flanked by Prrx1 (paired-related homeobox gene 1) and Scyc1 and define the order of, and distances between, loci as centromere–Prrx1–(0.7±0.7 cM)–Sele–(1.2±0.9 cM)–Scyc1–telomere. In the chicken, we isolated BAC clones containing PRRX1, SELE, and SCYC1 and positioned them by fluorescent in situ hybridization. SELE and PRRX1 mapped to the short arm of chicken Chr 8 and SCYC1 mapped to the region equivalent to 1q11–1q13 on the long arm of chicken Chr 1. The location of SELE on chicken Chr 8 was independently established by linkage analysis of COM0185, an (AT)16 microsatellite locus identified in a BAC clone that contained SELE. COM0185 was linked to several loci that mapped to one end of chicken Chr 8, with the order of loci, and genetic distances (in cM) between them defined as MSU0435, MSU0325–(7.8±3.7)–COM0185–(5.8±3.2)–ROS0338–(9.6±4.0)–ABR0322–(3.8±2.6)–GLUL. We have therefore positioned an evolutionary breakpoint in mammals and chickens between SELE and SCYC1. Furthermore, comparative mapping analysis of the RXRG–TNNT2 chromosomal segment that is conserved on human and mouse Chr 1 indicates that it is divided into four segments in the chicken, each of which maps to a different chromosome.


  • Open Access

    Comparisons of genomic structures and chromosomal locations of the mouse aldose reductase and aldose reductase‐like genes

    by Horace T. B. Ho, Nancy A. Jenkins, Neal G. Copeland, Debra J. Gilbert, Jeffrey A. Winkles, Helena W. Y. Louie, Fuk K. Lee, Stephen S. M. Chung, Sookja K. Chung

    Aldose reductase (AR), best known as the first enzyme in the polyol pathway of sugar metabolism, has been implicated in a wide variety of physiological functions and in the etiology of diabetic complications. We have determined the structures and chromosomal locations of the mouse AR gene (Aldor1) and of two genes highly homologous to Aldor1: the fibroblast growth factor regulated protein gene (Fgfrp) and the androgen regulated vas deferens protein gene (Avdp). The number of introns and their locations in the mouse Aldor1 gene are identical to those of rat and human AR genes and also to those of Fgfrp and Avdp. Mouse Aldor1 gene was found to be located near the Cald1 (Caldesmon) and Ptn (Pleiotropin) loci at the proximal end of chromosome 6. The closely related genes Fgfrp and Avdp were also mapped in this region of the chromosome, suggesting that these three genes may have arisen by a gene duplication event.